
Data supplement for Davidson et al., Efficacy and Safety of MIN-101: A 12-Week Randomized, Double Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry (doi: 10.1176/appi.ajp.2017.17010122)

FIGURE S1. Flowchart of Patients' Progress Through the Study



^{*} Including patients who dropped out after completion of Week 12 assessments due to refusal to be hospitalized at onset of open label phase: Placebo (n = 10); MIN-101 32 mg (n = 9); MIN-101 64 mg (n = 4)

